| __timestamp | ADMA Biologics, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9517014 | 7459000 |
| Thursday, January 1, 2015 | 7015946 | 11831000 |
| Friday, January 1, 2016 | 7688238 | 25705000 |
| Sunday, January 1, 2017 | 6229587 | 46181000 |
| Monday, January 1, 2018 | 3926120 | 59497000 |
| Tuesday, January 1, 2019 | 2343848 | 65003000 |
| Wednesday, January 1, 2020 | 5907013 | 74506000 |
| Friday, January 1, 2021 | 3646060 | 126006000 |
| Saturday, January 1, 2022 | 3613764 | 126215000 |
| Sunday, January 1, 2023 | 3300000 | 120161000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, ADMA Biologics, Inc. and Protagonist Therapeutics, Inc. have demonstrated contrasting strategies in their R&D expenditures.
From 2014 to 2023, Protagonist Therapeutics has consistently outpaced ADMA Biologics in R&D spending. In 2022, Protagonist's investment peaked at approximately $126 million, marking a staggering 1,590% increase from 2014. In contrast, ADMA Biologics' R&D expenses have seen a decline, with a 65% reduction from their 2014 peak of $9.5 million to $3.3 million in 2023.
These trends highlight Protagonist's aggressive pursuit of innovation, while ADMA's more conservative approach may reflect strategic reallocations or financial constraints. As the biotech sector evolves, these investment patterns could significantly influence each company's market position and technological advancements.
Who Prioritizes Innovation? R&D Spending Compared for Pfizer Inc. and Protagonist Therapeutics, Inc.
R&D Insights: How GSK plc and Protagonist Therapeutics, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and ADMA Biologics, Inc.
R&D Insights: How Bio-Techne Corporation and ADMA Biologics, Inc. Allocate Funds
R&D Insights: How Madrigal Pharmaceuticals, Inc. and ADMA Biologics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Ionis Pharmaceuticals, Inc. vs ADMA Biologics, Inc.
Research and Development: Comparing Key Metrics for TG Therapeutics, Inc. and ADMA Biologics, Inc.
ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.: SG&A Expense Trends
Amneal Pharmaceuticals, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Protagonist Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Research and Development: Comparing Key Metrics for Protagonist Therapeutics, Inc. and Travere Therapeutics, Inc.
Protagonist Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending